Evaluation of Racial Disparities in Hospice Use and End-of-Life Treatment Intensity in the REGARDS Cohort

Katherine A. Ornstein, PhD, MPH; David L. Roth, PhD; Jin Huang, PhD, MS; Emily B. Levitan, ScD; J. David Rhodes, MPH; Chanee D. Fabius, PhD, MA; Monika M. Safford, MD; Orla C. Sheehan, MD, PhD

Abstract

IMPORTANCE Although hospice use is increasing and patients in the US are increasingly dying at home, racial disparities in treatment intensity at the end of life, including hospice use, remain.

OBJECTIVE To examine differences between Black and White patients in end-of-life care in a population sample with well-characterized causes of death.

DESIGN, SETTING, AND PARTICIPANTS This study used data from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, an ongoing population-based cohort study with enrollment between January 25, 2003, and October 3, 2007, with linkage to Medicare claims data. Multivariable logistic regression models were used to examine racial and regional differences in end-of-life outcomes and in stroke mortality among 1212 participants with fee-for-service Medicare who died between January 1, 2013, and December 31, 2015, owing to natural causes and excluding sudden death, with oversampling of Black individuals and residents of Southeastern states in the United States. Initial analyses were conducted in March 2019, and final primary analyses were conducted in February 2020.

MAIN OUTCOMES AND MEASURES The primary outcomes of interest were hospice use of 3 or more days in the last 6 months of life derived from Medicare claims files. Other outcomes included multiple hospitalizations, emergency department visits, and use of intensive procedures in the last 6 months of life. Cause of death was adjudicated by an expert panel of clinicians using death certificates, proxy interviews, autopsy reports, and medical records.

RESULTS The sample consisted of 1212 participants (630 men [52.0%]; 378 Black individuals [31.2%]; mean [SD] age at death, 81.0 [8.6] years) of 2542 total deaths. Black decedents were less likely than White decedents to use hospice for 3 or more days (132 of 378 [34.9%] vs 385 of 834 [46.2%]; P < .001). After stratification by cause of death, substantial racial differences in treatment intensity and service use were found among persons who died of cardiovascular disease but not among patients who died of cancer. In analyses adjusted for cause of death (dementia, cancer, cardiovascular disease, and other) and clinical and demographic variables, Black decedents were significantly less likely to use hospice (odds ratio [OR], 0.72; 95% CI, 0.54-0.96) and more likely to have multiple emergency department visits (OR, 1.35; 95% CI, 1.01-1.80) and hospitalizations (OR, 1.39; 95% CI, 1.02-1.89) and undergo intensive treatment (OR, 1.94; 95% CI, 1.40-2.70) in the last 6 months of life compared with White decedents.

CONCLUSIONS AND RELEVANCE Despite the increase in the use of hospice care in recent decades, racial disparities in the use of hospice remain, especially for noncancer deaths. More research is required to better understand racial disparities in access to and quality of end-of-life care.

JAMA Network Open. 2020;3(8):e2014639. doi:10.1001/jamanetworkopen.2020.14639

Open Access. This is an open access article distributed under the terms of the CC-BY License.
Introduction

Consistent with patient preferences to avoid intensive hospital-based care at the end of life,1,2 in 2017, most US patients died at home.3 Use of hospice care is on the rise in the United States—with most deaths of Medicare beneficiaries occurring while receiving hospice care, a significant increase in the last decade.4 The fastest-growing segment of the population receiving hospice care includes individuals with noncancer diagnoses.5 Despite the potential benefits of hospice enrollment for individuals and families, including enhanced quality of life for patients near the end of life6-8 and decreased Medicare costs,9 half of patients with terminal illnesses still do not use hospice care.10 Furthermore, most individuals who use hospice care are admitted very close to the end of life. Short hospice stays (≤3 days) have increased to 28.4% of all hospice stays,10 and 14.3% of patients with cancer who enroll in hospice do so in the last 3 days of life.11 In addition, high-intensity treatments at the end of life remain common despite patient preferences to avoid such care. For example, among Medicare beneficiaries, intensive care unit use in the last month of life increased from 24% in 2000 to 29% in 2015.4

Research has documented racial differences in hospice use and end-of-life treatment intensity, consistent with a broad range of racial disparities in health care use and health outcomes. In general, Black decedents receive more aggressive care, have higher end-of-life health care spending, and are less likely to use hospice services than White decedents.12-14 Reasons for these disparities include preferences for more aggressive care, mistrust of the health care system, lack of in-home resources, and miscommunication and misunderstanding of treatment options.15

Because substantial shifts in end-of-life health care delivery have occurred, it is critical to better understand whether similar racial differences persist in the setting of different diseases. We used the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study linked to Medicare claims data to examine disparities in end-of-life care among individuals who have died of stroke, heart disease, cancer, dementia, or other serious illnesses. We hypothesized that high-intensity treatments at the end of life will be more common among Black than White decedents and that Black decedents will be less likely to use hospice care regardless of the cause of death.

Methods

Data Sources and Study Population

The data for this study are from REGARDS, an ongoing population-based cohort study of racial and regional differences in stroke mortality, with oversampling of Black individuals and residents of Southeastern states in the United States. The recruitment, enrollment, and assessment procedures of this national, population-based study are described in detail elsewhere.16 A total of 30,239 adults 45 years or older were enrolled between January 25, 2003, and October 3, 2007. Exclusion criteria included residence in or on a waiting list for a nursing home; cancer diagnosis requiring active treatment, such as chemotherapy or radiotherapy; and not speaking English. Every 6 months, follow-up telephone interviews are conducted with REGARDS enrollees to inquire about hospitalizations, outpatient visits, and any symptoms that might indicate possible study end points (eg, stroke and myocardial infarction). All REGARDS participants signed written informed consent statements that authorized the investigators to access their medical records to detect possible strokes, myocardial infarctions, and other medical events. This included permission to access electronic and administrative medical records, including Medicare claims. Medicare claims files have been successfully linked to REGARDS participants17 and examined in previous analyses of health care use.18,19 The REGARDS participants who died between January 1, 2013, and December 31, 2015, were included in this study, and the study was reviewed and approved by the institutional review boards of the University of Alabama at Birmingham and Johns Hopkins University. This report followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.20
Outcome Measures

Our primary outcomes of interest were hospice use and other measures of end-of-life treatment intensity within the last 6 months of life. All outcome variables were derived from Medicare fee-for-service (parts A and B) claims files. We focused on hospice use of 3 or more days as our primary measure to avoid capturing suboptimal hospice use owing to short duration. Next, building on previous work, we identified the use of 1 or more intensive life-sustaining medical procedures as determined by a review of International Classification of Diseases, Ninth Revision (ICD-9) codes or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes in each decedent's Medicare claims. These procedures included intubation and mechanical ventilation, tracheostomy, gastrostomy tube insertion, enteral or parenteral nutrition, hemodialysis, and cardiopulmonary resuscitation. Finally, we counted the number of emergency department (ED) admissions and inpatient hospitalizations in the 6-month period before death. Our primary focus was 2 or more ED visits and 2 or more hospital stays.

Main Exposure

Race in REGARDS is determined by self-report. Because the REGARDS study was designed to examine the factors that might explain the increased stroke mortality previously observed for Black individuals, only Black individuals and White individuals, who served as the reference group, were enrolled, and individuals who self-identified as Hispanic, Latino, Asian, or other races/ethnicities were excluded.

Covariates

Cause of death in the REGARDS study is adjudicated by an expert panel of clinicians using methods that are consistent with American Heart Association consensus guidelines. Death certificates, autopsy reports, and medical records from hospitalizations in the last 6 months of life were retrieved. Participant proxies (next of kin, family members, or close friends) were also interviewed to obtain information about the events surrounding the death. Each death is adjudicated independently by 2 expert clinicians who conduct their reviews using all information available at the time of review, including the participant's clinical baseline characteristics, death certificates, proxy interviews, the National Death Index, and medical records from recent hospital admissions. After individual review, the adjudicators agree on the underlying cause of death. Disagreements are resolved by consensus. Because of our interest in the decision to use hospice services, we excluded individuals who were determined by the adjudication panel to have experienced sudden death or death due to unnatural causes (10.8% [146 of 1358] of all deaths). For the present analyses, we grouped cause of death into the following 4 categories: cancer (all types); dementia; cardiovascular disease (CVD), including myocardial infarction, heart failure, stroke, and pulmonary embolism; and other, which included causes such as end-stage kidney disease, liver disease, infection, respiratory disease, and other medical problems not considered to be sudden deaths.

Demographic variables (sex, date of birth, marital status, annual household income, and educational level) were collected from a computer-assisted telephone interview conducted by trained interviewers at the time of enrollment into REGARDS. Location of residence was categorized based on census region and whether it was in the southern "stroke belt" region of the United States (1 of 8 states [North Carolina, South Carolina, Georgia, Tennessee, Alabama, Mississippi, Arkansas, and Louisiana] with high stroke mortality). The Charlson Comorbidity Index score was calculated using ICD-9 and ICD-10 diagnosis codes from the inpatient, outpatient, and physician claim (carrier) files for the 6-month period preceding death. These codes were then mapped to 17 comorbid conditions, weights were assigned, and the index was calculated. Medicaid dual-eligibility status was obtained from the Medicare beneficiary enrollment file.
Statistical Analysis

Initial analyses were conducted in March 2019, and final primary analyses were conducted in February 2020. Based on a conceptual framework of treatment intensity for patients with serious illness and a review of the literature, we first compared key clinical and demographic characteristics and markers of end-of-life treatment intensity by race. We used the χ² test, the t test, and the Wilcoxon rank sum test as appropriate. After stratifying by cause of death, we examined racial differences in markers of end-of-life treatment intensity. Next, we used multivariable logistic regression to examine the association of race with each of 4 outcomes: (1) hospice use of 3 or more days, (2) multiple (≥2) ED visits in the last 6 months of life, (3) multiple (≥2) hospital stays in the last 6 months of life, and (4) any use of intensive treatments in the last 6 months of life. Each model was adjusted for cause of death, sex, marital status, educational level, income, Charlson Comorbidity Index score, age at death, and Medicaid status. We also tested for interactions by race and cause of death for each outcome. SAS statistical software version 9.4 was used for all analyses (SAS Institute), and P < .05 was considered statistically significant. All tests were 2-tailed.

Results

We identified 1212 participants (630 men [52.0%]; 378 Black individuals [31.2%]; mean [SD] age at death, 81.0 [8.6] years) who constituted the study sample (Table 1). A total of 610 participants (50.3%) were married at the time of death, and 200 (16.5%) had less than a high school education. Decedents who died prior to 2013 were excluded owing to the unavailability of data on hospice use. Furthermore, decedents in REGARDS with no Medicare claims or who were enrolled only in Medicare part C were excluded. Among the 1358 REGARDS participants who died during the period from 2013 to 2015 with Medicare fee for service (parts A and B coverage) in the last 6 months of life, we further excluded 83 who had adjudicated sudden cause of death (eg, cardiac sudden deaths) and 54 who died owing to an accident, injury, suicide, or homicide. Among the remaining 1221 decedents, we excluded 9 with an undetermined cause of death and included 1212 with cause-of-death adjudication in the present analyses (eFigure in the Supplement).

As shown in Table 1, Black decedents were 2 years younger than White decedents at the time of death (mean [SD] age, 79.5 [9.2] vs 81.7 [8.1] years). Consistent with previously reported demographic differences for the REGARDS sample, Black participants in this analysis were less educated than White participants (less than high school education, 108 of 378 [28.6%] vs 92 of 834 [11.0%]) and more likely to have Medicaid dual eligibility (156 of 378 [41.3%] vs 97 of 834 [11.6%]). Black decedents also had more comorbidities at the time of death than White decedents (mean [SD] Charlson Comorbidity Index score, 5.1 [3.1] vs 4.1 [3.0]). Cause of death was determined as dementia, CVD, or cancer for 220 of 378 Black decedents (58.2%) and 501 of 834 White decedents (60.1%). The remaining causes of death were grouped together as other illness.

Black decedents were less likely than White decedents to use hospice for 3 or more days (132 of 378 [34.9%] vs 385 of 834 [46.2%]; P < .001) (Table 2). Black decedents also had a higher number of repeated hospitalizations and ED visits in the last 6 months of life than White decedents; 224 of 378 Black decedents (59.3%) were seen in the ED more than once in the last 6 months of life vs 387 of 834 White decedents (46.4%). Of 378 Black decedents, 190 (50.3%) had more than 1 hospitalization in the last 6 months of life compared with 300 of 834 White decedents (36.0%). For intensive procedures, Black decedents generally were 2 or more times as likely as White decedents to have received each procedure in the last 6 months of life. For example, 80 of 378 Black decedents (21.2%) were intubated or had mechanical ventilation compared with 94 of 834 White decedents (11.3%).

After stratifying by cause of death, we found substantial racial differences in treatment intensity among those with CVD deaths (Figure). Although there were no significant differences in hospice use, Black participants who died of CVD were significantly more likely than White decedents to have more than 1 ED visit (68 of 102 [66.7%] vs 87 of 195 [44.6%]) and multiple hospital stays (53 of 102 [51.5%] vs 156 of 378 [41.3%]).
[52.0%] vs 61 of 195 [31.3%]) and to have undergone intensive procedures (38 of 102 [37.3%] vs 34 of 195 [17.4%]). Similarly, among other deaths not attributed to cancer, dementia, or CVD, Black decedents were less likely to use hospice care (36 of 158 [22.8%] vs 120 of 333 [36.0%]) and significantly more likely than White decedents to have multiple ED visits (101 of 158 [63.9%] vs 154 of 333 [46.2%]) and multiple hospital stays (85 of 158 [53.8%] vs 129 of 333 [38.7%]) and to have undergone intensive procedures (70 of 158 [44.3%] vs 78 of 333 [23.4%]). Among cancer deaths, we did not observe statistically significant racial differences in treatment intensity among any indicators. Among participants whose cause of death was dementia, there was no significant difference in hospice use, ED visits, or hospitalizations by race, although Black decedents were significantly more likely to undergo intensive procedure use (6 of 37 [16.2%] vs 2 of 78 [2.6%]).

Our covariate-adjusted models are summarized in Table 3. Of primary interest is the association of race with outcomes after adjusting for covariates. Significant racial differences were found for all

### Table 1. Demographic and Clinical Characteristics of REGARDS Decedents by Race

| Variable                                      | Overall (N = 1212) | White (n = 834) | Black (n = 378) | P value |
|-----------------------------------------------|--------------------|----------------|----------------|---------|
| Age at REGARDS baseline, mean (SD), y         | 71.4 (8.5)         | 72.2 (8.2)     | 69.8 (9.1)     | <.001   |
| Age at death, mean (SD), y                    | 81.0 (8.6)         | 81.7 (8.2)     | 79.5 (9.2)     | <.001   |
| Female sex                                    | 582 (48.0)         | 366 (43.9)     | 216 (57.1)     | <.001   |
| Educational level                             |                    |                |                |         |
| <High school                                  | 200 (16.5)         | 92 (11.0)      | 108 (28.6)     | <.001   |
| High school graduate                          | 331 (27.3)         | 228 (27.3)     | 103 (27.3)     |         |
| Some college                                  | 323 (26.7)         | 227 (27.2)     | 96 (25.4)      |         |
| College graduate and above                    | 358 (29.5)         | 287 (34.4)     | 71 (18.8)      |         |
| Income, $                                      |                    |                |                |         |
| <20 000                                       | 247 (20.4)         | 117 (14.0)     | 130 (34.4)     |         |
| 20 000-34 000                                 | 357 (29.5)         | 247 (29.6)     | 110 (29.1)     | <.001   |
| 35 000-74 000                                 | 312 (25.7)         | 256 (30.7)     | 56 (14.8)      |         |
| ≥75 000                                       | 113 (9.3)          | 96 (11.5)      | 17 (4.5)       |         |
| Refused                                       | 183 (15.1)         | 118 (14.2)     | 65 (17.2)      |         |
| Marital status                                |                    |                |                |         |
| Married                                       | 610 (50.3)         | 476 (57.1)     | 134 (35.5)     |         |
| Single                                        | 44 (3.6)           | 20 (2.4)       | 24 (6.4)       | <.001   |
| Widowed                                       | 408 (33.7)         | 263 (31.5)     | 145 (38.4)     |         |
| Divorced                                      | 134 (11.1)         | 73 (8.8)       | 61 (16.1)      |         |
| Other                                         | 16 (1.3)           | 2 (0.2)        | 14 (3.7)       |         |
| Has Medicaid                                  | 253 (20.9)         | 97 (11.6)      | 156 (41.3)     | <.001   |
| Charlson Comorbidity Index score, mean (SD)   | 4.4 (3.1)          | 4.1 (3.0)      | 5.1 (3.1)      | <.001   |
| Depression measured via CES-D score, mean (SD)| 4.7 (4.7)          | 4.5 (4.6)      | 5.2 (5.0)      | .02     |
| Long-term care placement                      | 289 (23.8)         | 176 (21.1)     | 113 (29.9)     | <.001   |
| Cause of death                                |                    |                |                |         |
| CVD                                           | 297 (24.5)         | 195 (23.4)     | 102 (27.0)     | .16     |
| Cancer                                        | 309 (25.5)         | 228 (27.3)     | 81 (21.4)      |         |
| Dementia                                      | 115 (9.5)          | 78 (9.4)       | 37 (9.8)       |         |
| Other illness                                 | 491 (40.5)         | 333 (39.9)     | 158 (41.8)     |         |
| Lives alone                                   | 429 (35.4)         | 282 (33.8)     | 147 (38.9)     | .09     |
| Available caregiver                           | 971 (80.1)         | 680 (81.5)     | 291 (77.0)     | .07     |
| Stroke belta†                                  | 710 (58.6)         | 526 (63.1)     | 184 (48.7)     | <.001   |
| Census region                                 |                    |                |                |         |
| Northeast                                     | 76 (6.3)           | 46 (5.5)       | 30 (7.9)       | <.001   |
| Midwest                                       | 188 (15.5)         | 105 (12.6)     | 83 (22.0)      |         |
| South                                         | 874 (72.1)         | 628 (75.3)     | 246 (65.1)     |         |
| West                                          | 74 (6.1)           | 55 (6.6)       | 19 (5.0)       |         |

Abbreviations: CES-D, Center for Epidemiological Studies–Depression; CVD, cardiovascular disease; REGARDS, Reasons for Geographic and Racial Differences in Stroke. † Residence in one of the following 8 states with high stroke mortality: North Carolina, South Carolina, Georgia, Tennessee, Alabama, Mississippi, Arkansas, or Louisiana.
4 outcomes (hospice use ≥3 days, multiple ED visits, multiple hospital stays, and intensive procedure use in the last 6 months of life). Black decedents were less likely than White decedents to use hospice (adjusted odds ratio [aOR], 0.72; 95% CI, 0.54-0.96) and more likely to use all other forms of health care in the last 6 months of life. In particular, Black decedents were more likely to have multiple ED visits (aOR, 1.35; 95% CI, 1.01-1.80) and hospitalizations (aOR, 1.39; 95% CI, 1.02-1.89) and had nearly twice the odds of undergoing intensive procedures in the last 6 months of life (aOR, 1.94; 95% CI, 1.40-2.70).

Cause of death was strongly associated with hospice use and treatment intensity in our fully adjusted model. For example, patients who died of CVD were twice as likely as those with cancer to have multiple hospital visits (aOR, 1.78; 95% CI, 1.20-2.64) or ED visits (aOR, 2.00; 95% CI, 1.38-2.88) and 3 times as likely to undergo intensive procedures (aOR, 2.92; 95% CI, 1.86-4.60) but less likely to use hospice at the end of life (aOR, 0.25; 95% CI, 0.18-0.36) (Table 3). On the other hand, while dementia was associated with less hospice use (aOR, 0.62; 95% CI, 0.38-1.01) and more ED visits (aOR, 2.29; 95% CI, 1.39-3.79), there was no significant increase in the use of intensive procedures relative to those with cancer (aOR, 1.12; 95% CI, 0.48-2.59).

Interactions by race and cause of death were not significant for hospice use, multiple hospital visits, or intensive procedure use. A statistically significant interaction was detected for multiple ED visits, which suggests an increased association among Black patients with CVD or other illness compared with cancer (eTable in the Supplement). Relative to those dying of cancer, Black decedents with CVD or other illnesses had a 2-fold odds of multiple ED visits relative to White decedents.

Discussion

Consistent with Brown et al., we documented extensive racial differences in end-of-life treatment, with Black decedents receiving less hospice care and having more ED visits, hospitalizations, and intensive treatments in the 6 months immediately preceding death compared with White decedents. Although these findings remained even when we accounted for cause of death and other clinical and

| Table 2. End-of-Life Health Care Use in the Last 6 Months of Life, Overall and by Race |
|----------------------------------------|----------------|----------------|----------------|----------------|
| Variable                               | Overall (N = 1212) | White (n = 834) | Black (n = 378) | P value        |
| Hospice                                |                 |                |                |                 |
| Any hospice use                        | 643 (53.1) 643 (53.1) | 479 (57.4) 479 (57.4) | 164 (43.4) 164 (43.4) | <.001          |
| Hospice use ≥3 d                       | 517 (42.7) 517 (42.7) | 385 (46.2) 385 (46.2) | 132 (34.9) 132 (34.9) | <.001          |
| Total No. of days in hospice, median (IQR)* | 15.00 (5.00-59.00) 15.00 (5.00-59.00) | 13.00 (5.00-59.00) 13.00 (5.00-59.00) | 17.00 (5.00-58.50) 17.00 (5.00-58.50) | .35            |
| Healthcare use                         |                 |                |                |                 |
| ED visits                              | 956 (78.9) 956 (78.9) | 641 (76.9) 641 (76.9) | 315 (83.3) 315 (83.3) | .01            |
| ≥2 ED visits                           | 611 (50.4) 611 (50.4) | 387 (46.4) 387 (46.4) | 224 (59.3) 224 (59.3) | <.001          |
| No. of ED visits, mean (SD)*           | 2.5 (1.7) 2.5 (1.7) | 2.3 (1.6) 2.3 (1.6) | 2.8 (1.8) 2.8 (1.8) | <.001          |
| Hospital stays                         | 894 (73.8) 894 (73.8) | 593 (71.1) 593 (71.1) | 301 (79.6) 301 (79.6) | .002           |
| ≥2 Hospital stays                      | 490 (40.4) 490 (40.4) | 300 (36.0) 300 (36.0) | 190 (50.3) 190 (50.3) | <.001          |
| No. of hospital stays, mean (SD)*      | 2.0 (1.2) 2.0 (1.2) | 1.9 (1.1) 1.9 (1.1) | 2.2 (1.3) 2.2 (1.3) | <.001          |
| Intensive procedures                   |                 |                |                |                 |
| Tracheostomy                           | 17 (1.4) 17 (1.4) | 5 (0.6) 5 (0.6) | 12 (3.2) 12 (3.2) | <.001          |
| Gastrostomy tube                       | 51 (4.2) 51 (4.2) | 22 (2.6) 22 (2.6) | 29 (7.7) 29 (7.7) | <.001          |
| Hemodialysis                           | 70 (5.8) 70 (5.8) | 27 (3.2) 27 (3.2) | 43 (11.4) 43 (11.4) | <.001          |
| Enteral or parenteral nutrition        | 60 (5.0) 60 (5.0) | 29 (3.5) 29 (3.5) | 31 (8.2) 31 (8.2) | <.001          |
| CPR                                    | 53 (4.4) 53 (4.4) | 22 (2.6) 22 (2.6) | 31 (8.2) 31 (8.2) | <.001          |
| All intensive procedures               | 279 (23.0) 279 (23.0) | 148 (17.8) 148 (17.8) | 131 (34.7) 131 (34.7) | <.001          |

Abbreviations: CPR, cardiopulmonary resuscitation; ED, emergency department; IQR, interquartile range.

* Among those with any ED visits or hospital stays.
demographic characteristics in the analysis, we found that racial differences in treatment intensity were especially pronounced among those with noncancer diagnoses.

Although this study was not able to assess whether treatment-intensity measures were aligned with patient and family care treatment preferences, we know that most individuals report that they want less invasive care at the end of life.\textsuperscript{2,29} Several possible explanations may underlie the higher intensity of care received by Black decedents in our study. First, other studies have documented that lack of trust in the medical system by Black patients is associated with a reduced willingness to forgo life-sustaining measures\textsuperscript{30,31} and an increased use of the ED for usual care.\textsuperscript{32} Second, poor communications between Black patients and health care professionals are documented and may be associated with differences in the intensity of health care service use.\textsuperscript{33,34} In addition, cultural and spiritual differences may play an important role in choosing to forgo life-sustaining procedures.\textsuperscript{35} Black decedents may also have less access to higher-quality end-of-life care, including engagement in advance care planning in part owing to lower health literacy.\textsuperscript{36}

Our study afforded us the opportunity to examine racial differences in the context of rigorously ascertained causes of death. Consistent with other findings,\textsuperscript{37} underlying cause of death was strongly associated with hospice use after controlling for other factors. Persons without cancer were far less likely to use hospice care relative to individuals with a cancer-related cause of death. Several possible explanations exist for the observed discrepancy in hospice use based on underlying cause of death. Health care professionals who provide care for many common noncancer illnesses may lack awareness about the utility of hospice services. Low use of hospice care by patients without cancer may also be associated with poor prognostic accuracy for many common noncancer illnesses, such as CVD or dementia. Cancer trajectories are more predictable than noncancer disease trajectories.\textsuperscript{38}

\textbf{Figure. End-of-Life Health Care Use in the Last 6 Months of Life by Race and Cause of Death}

\textbf{A} CVD  
![Chart showing CVD healthcare use by race and cause of death with black and white bars, indicating statistical significance (P < .001)].

\textbf{B} Cancer  
![Chart showing cancer healthcare use by race and cause of death with black and white bars, indicating statistical significance (P < .001)].

\textbf{C} Dementia  
![Chart showing dementia healthcare use by race and cause of death with black and white bars, indicating statistical significance (P < .05)].

\textbf{D} Other  
![Chart showing other healthcare use by race and cause of death with black and white bars, indicating statistical significance (P < .001)].

CVD indicates cardiovascular disease; ED, emergency department.
Thus, it is easier for physicians to prognosticate when the life expectancy of a patient with cancer is 6 months or less, a criterion for hospice enrollment under the Medicare Hospice Benefit. Among cancer deaths, in fact, we did not find any racial differences in any marker of treatment intensity we examined, which suggests that the use of hospice care and more supportive care services may be more widely disseminated among those with advanced cancer, possibly reflecting the increased emphasis on end-of-life care for patients with cancer in the US health care system in recent years. Among decedents with dementia, we did not find any differences in hospice use, but we still saw a significant increase in the use of life-sustaining procedures among Black patients, a particularly troublesome finding given the lack of utility of these procedures at the end of life for this population.39,40

Despite an increased use of hospice care in the United States, there is a continued use of high-intensity treatments at the end of life,41 and significant differences by race and cause of death remain.4 Efforts to reduce disparities in the quality of end-of-life care must be prioritized. In particular, targeted efforts to increase advance care planning among Black and other racial minority populations should be expanded.42 The recent Centers for Medicare & Medicaid Services regulation to reimburse physicians and others for advance care planning discussions is another important step toward that goal.43 Reducing the stigma of hospice use through education and community outreach is critical.44,45 In particular, reducing disparities in hospice use in populations with noncancer causes of death will require improved prognostication, better patient-clinician communication, and rethinking current hospice outreach and enrollment practices.46,47

Using this national study with oversampling of Black participants, we had a large population to examine racial differences in end-of-life care. Furthermore, we had expert adjudication of the underlying cause of death and, hence, could examine differences in hospice use and other treatments by cause of death. We also included a marker of income. Disproportionate socioeconomic

| Variable                      | Odds ratio (95% CI)a       | Model 1 Model 2 | Model 1 Model 2 | Model 1 Model 2 | Model 1 Model 2 |
|-------------------------------|-----------------------------|-----------------|-----------------|-----------------|-----------------|
| Race, Black vs White          | 0.63 (0.49-0.81)            | 0.72 (0.54-0.96) | 1.68 (1.31-2.15) | 1.35 (1.01-1.80) | 1.80 (1.41-2.30) | 1.39 (1.02-1.89) | 2.46 (1.87-3.24) | 1.94 (1.40-2.70) |
| Cause of deathb               |                             |                 |                 |                 |                 |
| CVD                           | NA                          | 0.25 (0.18-0.36) | NA              | 2.00 (1.38-2.88) | NA              | 1.78 (1.20-2.64) | NA              | 2.92 (1.86-4.60) |
| Dementia                      | NA                          | 0.62 (0.38-1.01) | NA              | 2.29 (1.39-3.79) | NA              | 1.74 (0.98-3.08) | NA              | 1.12 (0.48-2.59) |
| Other illness                 | NA                          | 0.23 (0.17-0.32) | NA              | 2.00 (1.44-2.78) | NA              | 2.32 (1.63-3.35) | NA              | 3.97 (2.64-5.98) |
| Female sex                    | NA                          | 1.25 (0.95-1.65) | NA              | 1.19 (0.90-1.58) | NA              | 1.61 (1.18-2.18) | NA              | 1.16 (0.83-1.62) |
| Age at death                  | NA                          | 1.03 (1.02-1.05) | NA              | 1.01 (1.00-1.03) | NA              | 1.00 (0.99-1.02) | NA              | 0.95 (0.93-0.97) |
| Educational level, college vs | NA                          | 0.96 (0.73-1.27) | NA              | 0.80 (0.60-1.05) | NA              | 0.92 (0.68-1.26) | NA              | 0.91 (0.64-1.29) |
| Marital status: married vs    | NA                          | 1.21 (0.91-1.61) | NA              | 1.06 (0.79-1.41) | NA              | 1.17 (0.85-1.60) | NA              | 1.16 (0.82-1.64) |
| income, $                     |                             |                 |                 |                 |                 |
| ≥75 000 vs <75 000            | NA                          | 1.06 (0.69-1.65) | NA              | 1.24 (0.79-1.94) | NA              | 0.90 (0.55-1.46) | NA              | 0.83 (0.48-1.43) |
| Refused vs <75 000            | NA                          | 0.75 (0.53-1.07) | NA              | 0.80 (0.56-1.13) | NA              | 0.73 (0.50-1.08) | NA              | 0.92 (0.60-1.40) |
| Dual eligible for Medicare    | NA                          | 1.12 (0.80-1.56) | NA              | 0.91 (0.65-1.27) | NA              | 0.77 (0.54-1.11) | NA              | 0.81 (0.54-1.20) |
| Charlson Comorbidity Index    | NA                          | 0.94 (0.90-0.99) | NA              | 1.33 (1.27-1.40) | NA              | 1.50 (1.42-1.59) | NA              | 1.21 (1.15-1.28) |

Abbreviations: CVD, cardiovascular disease; ED, emergency department; NA, not applicable.

*a Model 1, unadjusted; model 2, adjusted for all variables listed.

*b Referent group is cancer.
disadvantage is associated with some, but not all, of the differences in health care intensity at the end of life by race. Although our study was able to detect differences by race, larger studies are required to better examine interactions by race, educational level, and cause of death to understand the mechanisms by which disparities may exist.

Limitations
Our findings should be interpreted with a number of potential limitations in mind. We were limited to decedents with Medicare (in particular, those who had fee-for-service Medicare 6 months before death). Those excluded were younger, more likely to be Black, and had lower income. Our results therefore may not be generalizable to all decedents. Although we were able to identify deaths due to cancer, CVD, and dementia, our dementia decedent subgroup was too small to capture meaningful differences. This group in particular requires further study given the growing prevalence of persons living with dementia and the need for better treatment at the end of life, including appropriate hospice care use. Dementia may also have been underdiagnosed in our sample of patients who did not have routine cognitive testing, with differential diagnosis by race. In addition, we grouped together multiple causes of death as “other illness.” Although we examined differences between Black and White decedents, we were unable to examine other racial groups that were excluded by design in REGARDS. Our work regarding differences in care may still be applicable to other disadvantaged populations. Furthermore, while we included careful adjustment of variables in models, there may still be residual confounding. Finally, we did not have detailed information on patient and family treatment preferences, whether treatment was concordant with care received, prognostic uncertainty, or overall satisfaction with the care received. These factors are likely to vary by disease status and should be explored further.

Conclusions
Our work suggests that Black decedents undergo more intensive treatments at the end of life and are less likely to use hospice services relative to White decedents. More sustained efforts must be made to reduce disparities in end-of-life care through efforts to better educate and train health care professionals and to promote the discussion of personal values and treatment preferences for the end of life in Black populations.
**REFERENCES**

1. Barnato AE, Herndon MB, Anthony DL, et al. Are regional variations in end-of-life care intensity explained by patient preferences?: a study of the US Medicare population. *Med Care*. 2007;45(5):386-393. doi:10.1097/01.mlr.0000255248.79308.41

2. Teno JM, Fisher ES, Hamel MB, Coppola K, Dawson NV. Medical care inconsistent with patients’ treatment goals: association with 1-year Medicare resource use and survival. *J Am Geriatr Soc*. 2002;50(3):496-500. doi:10.1046/j.1532-5415.2002.50116.x

3. Cross SH, Warraich HJ. Changes in the place of death in the United States. *N Engl J Med*. 2019;381(24):2369-2370. doi:10.1056/NEJMe1911982

4. Teno JM, Gozalo P, Trivedi AN, et al. Site of death, place of care, and health care transitions among US Medicare beneficiaries, 2000-2015. *JAMA*. 2018;320(3):264-271. doi:10.1001/jama.2018.8981

5. Aldridge MD, Canavan M, Cherlin E, Bradley EH. Has hospice use changed? 2000-2010 utilization patterns. *Med Care*. 2015;53(1):95-101. doi:10.1097/MLR.0000000000000256

6. Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD, Prigerson HG. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers’ mental health. *J Clin Oncol*. 2010;28(29):4457-4464. doi:10.1200/JCO.2009.26.3863

7. Teno JM, Shu JE, Casarett D, Spence C, Rhodes R, Connor S. Timing of referral to hospice and quality of care: length of stay and bereaved family members’ perceptions of the timing of hospice referral. *J Pain Symptom Manage*. 2007;34(2):120-125. doi:10.1016/j.jpainsymman.2007.04.014

8. Carlson MD, Herrin J, Du Q, et al. Impact of hospice disenrollment on health care use and Medicare expenditures for patients with cancer. *J Clin Oncol*. 2010;28(28):4371-4375. doi:10.1200/JCO.2009.26.1818

9. Kelso AS, Deb P, Du Q, Aldridge Carlson MD, Morrison RS. Hospice enrollment saves money for Medicare and improves care quality across a number of different lengths-of-stay. *Health Aff (Millwood)*. 2013;32(3):552-561. doi:10.1377/hlthaff.2012.0851

10. Teno JM, Gozalo PL, Bynum JP, et al. Change in end-of-life care for Medicare beneficiaries: site of death, place of care, and health care transitions in 2000, 2005, and 2009. *JAMA*. 2013;309(5):470-477. doi:10.1001/jama.2012.207624

11. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayajian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? *J Clin Oncol*. 2008;26(23):3860-3866. doi:10.1200/JCO.2007.15.8253
12. Byhoff E, Harris JA, Langa KM, Iwashyna TJ. Racial and ethnic differences in end-of-life Medicare expenditures. *J Am Geriatr Soc*. 2016;64(9):1789-1797. doi:10.1111/jgs.14263

13. Kelley AS, Ettner SL, Morrison RS, Du Q, Wenger NS, Sarkisian CA. Determinants of medical expenditures in the last 6 months of life. *Ann Intern Med*. 2011;154(4):235-242. doi:10.7326/0003-4819-154-4-2010120150-00004

14. Barnato AE, Berhane Z, Weissfeld LA, Chang CC, Linde-Zwirble WT, Angus DC; Robert Wood Johnson Foundation ICU End-of-Life Peer Group. Racial variation in end-of-life intensive care use: a race or hospital effect? *Health Serv Res*. 2006;41(6):2219-2237. doi:10.1111/j.1475-6773.2006.00598.x

15. LoPresti MA, Dement F, Gold HT. End-of-life care for people with cancer from ethnic minority groups: a systematic review. *Am J Hosp Palliat Care*. 2016;33(3):291-305. doi:10.1177/1049909114565658

16. Howard VJ, Cushman M, Pulley L, et al. The Reasons for Geographic and Racial Differences in Stroke study: objectives and design. *Neuroepidemiology*. 2005;25(3):135-143. doi:10.1159/000086678

17. Xie F, Colantonio LD, Curtis JR, et al. Linkage of a population-based cohort with primary data collection to Medicare claims: the Reasons for Geographic and Racial Differences in Stroke study. *Am J Epidemiol*. 2016;184(7):532-544. doi:10.1093/aje/kww077

18. Blackburn J, Albright KC, Haley WE, et al. Men lacking a caregiver have greater risk of long-term nursing home placement after stroke. *J Am Geriatr Soc*. 2018;66(1):133-139. doi:10.1111/jgs.15166

19. Roth DL, Sheehan DC, Huang J, et al. Medicare claims indicators of healthcare utilization differences after hospitalization for ischemic stroke: race, gender, and caregiving effects. *Int J Stroke*. 2016;11(8):928-934. doi:10.1177/1747493016660095

20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med*. 2007;147(8):573-577. doi:10.7326/0003-4819-147-8-200710160-00010

21. Luta X, Maessen M, Egger M, Stuck AE, Goodman D, Clough-Gorr KM. Measuring intensity of end of life care: a systematic review. *PloS One*. 2015;10(4):e0123764. doi:10.1371/journal.pone.0123764

22. Tschirhart EC, Du Q, Kelley AS. Factors influencing the use of intensive procedures at the end of life. *J Am Geriatr Soc*. 2014;62(11):2088-2094. doi:10.1111/jgs.13104

23. Barnato AE, Farrell MH, Chang CC, Lave JR, Roberts MS, Angus DC. Development and validation of hospital “end-of-life” treatment intensity measures. *Med Care*. 2009;47(10):1098-1105. doi:10.1097/MLR.Ob013e3181993191

24. Ornstein KA, Aldridge MD, Garrido MM, et al. The use of life-sustaining procedures in the last month of life is associated with more depressive symptoms in surviving spouses. *J Pain Symptom Manage*. 2017;53(2):178-187.e1. doi:10.1016/j.jpainsymman.2016.08.023

25. Halanych JH, Shuaib F, Parmar G, et al. Agreement on cause of death between proxies, death certificates, and clinician adjudicators in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. *Am J Epidemiol*. 2011;173(11):1319-1326. doi:10.1093/aje/kwr033

26. Olubowale OT, Safford MM, Brown TM, et al. Comparison of expert adjudicated coronary heart disease and cardiovascular disease mortality with the national death index: results from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. *J Am Heart Assoc*. 2016;5(5):e004966. doi:10.1161/JAHA.116.004966

27. Kelley AS, Morrison RS, Wenger NS, Ettner SL, Sarkisian CA. Determinants of treatment intensity for patients with serious illness: a new conceptual framework. *J Palliat Med*. 2010;13(7):807-813. doi:10.1089/jpm.2010.0007

28. Brown CE, Engelberg RA, Sharma R, et al. Race/ethnicity, socioeconomic status, and healthcare intensity at the end of life. *J Palliat Med*. 2018;21(9):1308-1316. doi:10.1089/jpm.2018.0011

29. Silveira MJ, Kim SY, Langa KM. Advance directives and outcomes of surrogate decision making before death. *N Engl J Med*. 2010;362(13):1211-1218. doi:10.1056/NEJMoa0907901

30. Degenholtz HB, Thomas SB, Miller MJ. Race and the intensive care unit: disparities and preferences for end-of-life care. *Crit Care Med*. 2003;31(5)(suppl):S373-S378. doi:10.1097/01.CCM.0000065121.62144.0D

31. Hopp FP, Duffy SA. Racial variations in end-of-life care. *J Am Geriatr Soc*. 2000;48(6):658-663. doi:10.1111/j.1532-5415.2000.tb04724.x

32. Arnett MJ, Thorpe RJ Jr, Gaskin DJ, Bowie JV, LaVeist TA. Race, medical mistrust, and segregation in primary care as usual source of care: findings from the Exploring Health Disparities in Integrated Communities Study. *J Urban Health*. 2016;93(3):456-467. doi:10.1007/s11524-016-0054-9
33. Palmer NR, Kent EE, Forsythe LP, et al. Racial and ethnic disparities in patient-provider communication, quality-of-care ratings, and patient activation among long-term cancer survivors. J Clin Oncol. 2014;32(36):4087-4094. doi:10.1200/JCO.2014.55.5060

34. Mack JW, Paulk ME, Viswanath K, Prigerson HG. Racial disparities in the outcomes of communication on medical care received near death. Arch Intern Med. 2010;170(17):1533-1540. doi:10.1001/archinternmed.2010.322

35. Cooper Z, Rivara FP, Wang J, Mackenzie EJ, Jurkovich GJ. Racial disparities in intensity of care at the end-of-life: are trauma patients the same as the rest? J Health Care Poor Underserved. 2012;23(2):857-874. doi:10.1353/hpu.2012.0064

36. Hong M, Yi EH, Johnson KJ, Adamek ME. Facilitators and barriers for advance care planning among ethnic and racial minorities in the U.S.: a systematic review of the current literature. J Immigr Minor Health. 2018;20(5):1277-1287. doi:10.1007/s10903-017-0670-9

37. Chung K, Burke SC. Characteristics of hospice patients utilizing hospice inpatient/residential facilities. Am J Hosp Palliat Care. 2013;30(7):640-647. doi:10.1177/104990912469717

38. Teno JM, Weitzman S, Fennell ML, Mor V. Dying trajectory in the last year of life: does cancer trajectory fit other diseases? J Palliat Med. 2001;4(4):457-464. doi:10.1089/jpm.2001.4.457

39. Mitchell SL. Clinical practice: advanced dementia. N Engl J Med. 2015;372(26):2533-2540. doi:10.1056/NEJMcp1412652

40. Mitchell SL, Morris JN, Park PS, Fries BE. Terminal care for persons with advanced dementia in the nursing home and home care settings. J Palliat Med. 2004;7(6):808-816. doi:10.1089/jpm.2004.7.808

41. Teno JM, Freedman VA, Kasper JD, Gozalo P, Mor V. Is care for the dying improving in the United States? J Palliat Med. 2015;18(8):662-666. doi:10.1089/jpm.2015.0039

42. Pecanac KE, Repenshek MF, Tennenbaum D, Hammes BJ. Respecting Choices and advance directives in a diverse community. J Palliat Med. 2014;17(3):282-287. doi:10.1089/jpm.2013.0047

43. Dept of Health and Human Services; Centers for Medicare & Medicaid Services. Medicare program: revisions to payment policies under the physician fee schedule and other revisions to part B for CY 2016; final rule with comment period. Fed Regist. 2015;80(220):70885-71386.

44. Allsop MJ, Ziegler LE, Mulvey MR, Russell S, Taylor R, Bennett MI. Duration and determinants of hospice-based specialist palliative care: a national retrospective cohort study. Palliat Med. 2018;32(8):1322-1333. doi:10.1177/0269216318781417

45. Rhodes RL, Batchelor K, Lee SC, Halm EA. Barriers to end-of-life care for African Americans from the providers' perspective: opportunity for intervention development. Am J Hosp Palliat Care. 2015;32(2):137-143. doi:10.1177/104990913507127

46. Kirollos I, Tamariz L, Schultz EA, Diaz Y, Wood BA, Palacio A. Interventions to improve hospice and palliative care referral: a systematic review. J Palliat Med. 2014;17(8):957-964. doi:10.1089/jpm.2013.0503

47. Lee J, Cagle JG. Factors associated with opinions about hospice among older adults: race, familiarity with hospice, and attitudes matter. J Palliat Care. 2017;32(3-4):101-107. doi:10.1177/0825859717738441

48. Amjad H, Roth DL, Sheehan OC, Lyketsos CG, Wolff JL, Samus QM. Underdiagnosis of dementia: an observational study of patterns in diagnosis and awareness in US older adults. J Gen Intern Med. 2018;33(7):1131-1138. doi:10.1007/s11606-018-4377-y

SUPPLEMENT.

eFigure. Derivation of Analytic Sample

eTable. Interaction of Race and Cause of Death on End-of-Life Treatment Intensity